期刊文献+

两种国产注射用伏立康唑与输液配伍稳定性研究 被引量:15

Study the compatibility stability of two kinds of homebred voriconazole for injection and infusion
下载PDF
导出
摘要 目的考察两种国产注射用伏立康唑与输液配伍稳定性。方法测定用5%葡萄糖注射液、0.9%氯化钠注射液稀释注射用伏立康唑后的性状、p H值、不溶性微粒变化,用紫外分光光度法测定含量变化。结果以羟丙基-β-环糊精为辅料的注射用伏立康唑用这两种输液稀释后在7h内含量、不溶性微粒、p H值无改变,但用0.9%氯化钠注射液稀释时产生的不溶性微粒相对比用5%葡萄糖注射液稀释的多;以专用溶媒溶解的注射用伏立康唑在用0.9%氯化钠注射液稀释20min后,用5%葡萄糖注射液稀释3h以上产生浑浊,药物结晶析出,含量下降。结论 两种注射用伏立康唑均应用5%葡萄糖注射液稀释后静脉滴注,专用溶媒溶解的注射用伏立康唑用5%葡萄糖注射液稀释至2mg/m L后立即注射,避免长时间放置析出结晶。 Objective To investigate the compatibility stability of two kinds of homebred voriconazole for injection, which hydroxypropyl β-cyclodextrin or mixture ofpropylene glycol and ethanol as special solvent. Methods Determining the variation of compatibility voriconazole for injection dilute in 5% glucose injection or 0.9% sodium chloride injection. The characters, pH, insoluble particles, and the content were measured by UV determination. Results Voriconazole with hydroxypropyl β-cyclodextrin soluted in 5% glucose or 0.9% sodium chloride were no changes in content, insoluble particles and pH for 7 hours. But there were more insoluble particles soluted in 0.9% sodium chloride than in 5% glucose injection. They would generate crystal precipitation and the vorieonazole content decreased with special menstruum diluted with 0.9% sodium chloride after 20 minutes or with 5% glucose diluted after 3 hours. Conclusion Two kinds ofvoriconazole for injection should be diluted in 5% glucose injection. Voriconazole with special menstruum diluted in 5% glucose injection should be used immediately.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2015年第2期120-123,共4页 Chinese Journal of Antibiotics
关键词 注射用伏立康唑 羟丙基-Β-环糊精 专用溶媒 Voriconazole for injection Hydroxypropyl β-cyclodextrim Special solvent
  • 相关文献

参考文献4

二级参考文献27

  • 1武雪芬,郑晓珂,姚宏建,费娜.丹皮酚包合物的热稳定性考察和形成常数测定[J].中国中药杂志,2005,30(7):501-503. 被引量:15
  • 2张传海,徐飞.抗真菌新药伏立康唑[J].社区医学杂志,2005,3(11):30-31. 被引量:5
  • 3丁平田,吴雪梅.药物制剂的新型辅料2-羟丙基-β-环糊精[J].国外医药(合成药.生化药.制剂分册),1996,17(2):107-111. 被引量:62
  • 4Ng A W, Wasan K M, Lopez-Berestetin G. Development posomal polyene antibiotics: an historical perspective [J].J Pharm Sci,2003,6:67.
  • 5Hitchcock C A, Pye G W, Oliver G P, et al. UK-109,496; a novel, wide-spectrum triazol derivative for the treatment of fungal infection: antifungal activity and selectivity in vitro [C]. Washington D C. Microbiology Asf. 35th Intersciences conference on antimicrobial agents and chemotherapy, 1995.
  • 6Groll A H, Piscitelli S C, Walsh T J. Clinical pharmacology of systemic antifungal agents.. A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development [J]. Adv Pharmacol, 1998,44:343.
  • 7Mora-Duarte J, Betts R, Rotstein C, et al, Comparison of caspofungin and amphotericin B for invasive candidiasis [J]. N Engl J Med,2002,347:2020.
  • 8Verduyn Lunel F M, Meis J F, Voss A. Nosocomial fungal infections: candidemia [J]. Diagn Microbiol Infect Dis,1999,34:213.
  • 9Kullberg B J, Oude Lashot A M. Epidemiology of opportunistic invasive mycoses [J]. Eur J Med Re.s, 2002,7: 183.
  • 10Ellis M. Invasive fungal infections: evolving challenges for diagnosis and therapeutics [J]. Mol Immunol, 2001,38:947.

共引文献36

同被引文献143

引证文献15

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部